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Abstract.
Background: Intraputamenal glial cell line-derived neurotrophic factor (GDNF), administered every 4 weeks to patients
with moderately advanced Parkinson’s disease, did not show significant clinical improvements against placebo at 40 weeks,
although it significantly increased [18F]DOPA uptake throughout the entire putamen.
Objective: This open-label extension study explored the effects of continued (prior GDNF patients) or new (prior placebo
patients) exposure to GDNF for another 40 weeks.
Methods: Using the infusion protocol of the parent study, all patients received GDNF without disclosing prior treatment
allocations (GDNF or placebo). The primary outcome was the percentage change from baseline to Week 80 in the OFF state
Unified Parkinson’s Disease Rating Scale (UPDRS) motor score.
Results:All 41 parent study participants were enrolled. The primary outcome decreased by 26.7 ± 20.7% in patients on GDNF
for 80 weeks (GDNF/GDNF; N = 21) and 27.6 ± 23.6% in patients on placebo for 40 weeks followed by GDNF for 40 weeks
(placebo/GDNF, N = 20; least squares mean difference: 0.4%, 95% CI: –13.9, 14.6, p = 0.96). Secondary endpoints did not
show significant differences between the groups at Week 80 either. Prespecified comparisons between GDNF/GDNF at Week
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80 and placebo/GDNF at Week 40 showed significant differences for mean OFF state UPDRS motor (–9.6 ± 6.7 vs. –3.8 ± 4.2
points, p = 0.0108) and activities of daily living score (–6.9 ± 5.5 vs. –1.0 ± 3.7 points, p = 0.0003). No treatment-emergent
safety concerns were identified.
Conclusions: The aggregate study results, from the parent and open-label extension suggest that future testing with GDNF
will likely require an 80- rather than a 40-week randomized treatment period and/or a higher dose.
Keywords: Glial cell line-derived neurotrophic factor, convection enhanced delivery, Parkinson’s disease, neurorestoration
INTRODUCTION
Glial cell line-derived neurotrophic factor (GDNF)
is known for its neurorestorative and neuropro-
tective effects in nonhuman primate models of
Parkinson’s disease [1]. However, despite promis-
ing results in early open-label clinical studies [2,
3], placebo-controlled trials testing GDNF as a
disease-modifying treatment for this relentlessly pro-
gressing disease have not shown significant clinical
benefit to date [4, 5]. In particular, as recently
reported, treatment with fixed-dose GDNF intraputa-
menal infusions, administered every 4 weeks, did not
show a significant improvement against placebo in
OFF state Unified Parkinson’s Disease Rating Scale
(UPDRS) motor score (part III) or other clinical
endpoints at 40 weeks, although spatial delivery of
GDNF sufficient to achieve a significant increase in
[18F]DOPA uptake across the entire putamen was
achieved [5].
The trial reported here is an open-label extension of
the latter study and was performed under a separate
protocol. This open label extension trial was initi-
ated before the results from the double-blind parent
investigation were known. It was developed to enable
prior parent study placebo patients to receive GDNF,
to gain longer term safety data, and to gather further
exploratory information on GDNF clinical effects fol-
lowing a longer period of repeated tissue exposures.
Recognizing the caveats of an open label clinical trial,
it was hoped that this data may help to explore the
effects of GDNF when administered every 4 weeks
via a skull-mounted port, in a manner to achieve
bilateral intraputamenal convection-enhanced deliv-
ery (CED), for a total of 80 weeks.
MATERIALS AND METHODS
Study design and structure
This single-center, open-label trial of intermit-
tent bilateral intraputamenal infusions of GDNF
administered via CED was a direct continuation of
the preceding randomized double-blind parent study
recently reported [5]. All parent study completers had
the option to enroll in the extension investigation that
was conducted at the same center in Bristol, UK.
Post-screening in the parent study, eligible patients
underwent robot-assisted surgery for stereotactic
implantation of the in-house CED system specified
by the lead neurosurgeon (SSG), comprising four sep-
arate intraputamenal infusion catheters and a single
skull-mounted transcutaneous port [5].
All patients were treated with GDNF intraputame-
nal infusions every 4 weeks using the dose regimen
and intermittent infusion parameters employed in
the parent study [5]. In an attempt to minimize
the bias associated with the open design, treatment
allocation during the parent study was only dis-
closed to patients after the database for the extension
trial was locked. While being aware that they were
receiving GDNF in the extension study, patients
did not know, therefore, whether they had been
on GDNF or placebo in the parent study. Further-
more, the only information on parent study outcome
that was provided to participants or made pub-
licly available before locking the extension study
database was that the primary endpoint of the double-
blind study had not been met. As in the parent
study, throughout the extension trial, trained raters
blinded to all other aspects of the patients’ condi-
tion and their prior treatment assignments performed
motor scoring.
The study was registered through the EU Clinical
Trials Register (EudraCT Number, 2013-001881-40).
Local institutional approval was obtained including
protocol approval, the study was executed in accord
with the Helsinki Declaration of 1975 and all patients
provided written informed consent. The Trial Steer-
ing Committee and an independent Data Monitoring
Committee provided clinical oversight. The authors
vouch for the accuracy and completeness of the data
and for adherence to the study protocol (see Supple-
mentary Material, Appendix A, for study protocol
first and final versions as well as a summary of pro-
tocol amendments).
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Patients
From October 2013 through to April 2016, all 41
patients completing the parent study were screened
for participation in the extension trial (see Supple-
mentary Material, Appendix B, for CONSORT flow
diagram). At entry in the parent study, patients were
between 35 and 75 years old and presented with motor
symptom duration ≥5 years, moderate disease sever-
ity (Hoehn and Yahr stage 2-3 and UPDRS motor
score 25–45, both in a practically defined OFF state),
motor fluctuations (average of at least 2.5 hours of
OFF time per day on 3-day fluctuation diaries), and
levodopa responsiveness defined as ≥40% improve-
ment in UPDRS motor score following a levodopa
challenge. Exclusion criteria in the extension study
were early discontinuation of treatment or signifi-
cant protocol deviation in the parent study, presence
of clinically significant depression, cognitive decline
(Montreal Cognitive Assessment [MoCA] < 24), or
any new medical condition that might impair outcome
measure assessments or safety.
Study procedures and assessments
The schedule for study procedures and assessments
in the parent study was continued in the extension.
Where applicable, visits are designated both by the
consecutive week number from baseline in the parent
study and the extension study week number (denoted
by “e”).
Patients returned within a week after completing
the parent study to receive the first of 10 sched-
uled GDNF treatments at 4-week intervals (Weeks
40/e0 to 76/e36). At each treatment, 400L infusate
(300L GDNF followed by 100L artificial CSF
[aCSF]) were delivered per each of the 4 catheters.
The concentration of GDNF in the infusate was
0.2g/L, and the total dose of GDNF given per
4 weeks was 240g (120g per putamen).
The protocol stated that Parkinson’s medication
was to be kept stable during the study where pos-
sible but could be modified if required for symptom
control.
Every 8 weeks, starting at Week 48/e8, patients
completed 3-day diary recordings and underwent
assessments of motor function in the practically
defined OFF state and post an L-dopa challenge.
All patients had been previously trained in the
completion of PD diary recordings. Motor assess-
ments were performed immediately prior to the
GDNF administrations to reduce the risk of potential
symptomatic effects from putamenal infusions per
se. Other efficacy outcome measures were assessed
at wider intervals (see study protocol, Supplemen-
tary Material, Appendix A). Samples for anti-GDNF
antibodies and GDNF plasma concentrations were
collected throughout the study. As in the parent inves-
tigation, catheter performance was verified at Week
80/e40 through an intraputamenal test infusion of a
2 mM solution of gadolinium in aCSF followed by
MRI scan. [18F]DOPA positron emission tomogra-
phy (PET) scans were not acquired in the extension
study.
Study outcomes
The primary endpoint of the study was the percent-
age change from baseline (Week 0) to Week 80/e40
in the practically defined OFF state UPDRS motor
score, comparing the group that had received GDNF
in the parent investigation followed by open-label
GDNF (GDNF/GDNF) versus the group that received
placebo in the parent investigation followed by open-
label GDNF (placebo/GDNF).
Secondary endpoints included absolute change
from baseline in OFF state UPDRS motor score, as
well as absolute and percentage change from base-
line in UPDRS motor score in the ON state and
UPDRS activities of daily living (ADL; part II) and
total (sum of motor and ADL) scores in the OFF and
ON state, change in UPDRS part I and IV scores, and
change from baseline in Parkinson’s disease diary
ratings. A further prespecified secondary endpoint
included comparing Week 80/e40 UPDRS scores
in the GDNF/GDNF group against Week 40 scores
in the placebo/GDNF group (i.e., at the end of the
placebo treatment).
Supplementary endpoints included timed motor
tests in both OFF and ON state, total daily lev-
odopa and levodopa equivalent dose, the non-motor
symptom scale for PD (NMSS), cognitive, mood and
impulsivity measures, the University of Pennsylvania
smell test (UPSIT), and Parkinson-related quality of
life questionnaires (PDQ-39 and EQ-5D). Patients’
satisfaction and impact on quality of life in relation
to the delivery device were not specifically explored.
A prospective responder analysis was performed
to identify patients demonstrating a ≥ 10 absolute
points improvement in OFF state UPDRS motor score
and/or a ≥ 1-hour gain in total good-quality ON time
per day. Good-quality ON time was defined as ON
time with either no dyskinesia or non-troublesome
dyskinesia as per the patient-reported diaries. Post
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hoc, it was decided to also include patients showing
≥5 points improvement in OFF state ADL score in
the responder analysis.
UPDRS motor and ADL score assessments, timed
taps and timed walks were completed by three trained
raters who were blinded to all other aspects of the
patients’ condition and remained blinded to the treat-
ment allocation during the preceding double-blind
parent trial. Wherever possible, the same rater that
performed the baseline (Week 0) assessment also
performed the Week 80/e40 assessment. All OFF
assessments were performed at a similar time in the
morning, following withholding of long-acting PD
medications the day before and all other Parkinson’s
disease medications from 6 pm the evening before.
During screening for the parent investigation,
patients were trained on the completion of the Parkin-
son’s disease diary and had to demonstrate their
ability to accurately determine their ON/OFF state
as part of the inclusion criteria.
Imaging endpoints included change from baseline
to Week 80/e40 in gadolinium-evidenced volume of
infusate distribution, putamenal volume of interest
coverage (VOI; the dorsal two thirds of the posterior
putamen) and total putamenal coverage as assessed
on T1-weighted MRIs.
Safety was assessed on the basis of adverse events
(AEs), routine laboratory testing and anti-GDNF
antibodies. All AEs were considered treatment-
emergent. Dyskinesias, falls, adverse changes in
mood, and impulsivity were tabulated as AEs of spe-
cial interest. Furthermore, patients were monitored
for cognitive function (MoCA and Mattis Dementia
Rating Scale) and signs of impulsive or compulsive
behavior (questionnaire for impulsive-compulsive
disorders in Parkinson’s disease).
Statistical analysis
Statistical analyses, as prespecified in the statisti-
cal analysis plan (SAP; see Supplementary Material,
Appendix C for first and final versions of SAP as well
as a summary of SAP amendments), were conducted
with the use of Statistical Analysis System (SAS)
software, version 9.4 (SAS Institute). Any hypothe-
sis testing was performed with a 2-sided alternative at
an alpha level of 0.05. No adjustments for multiplicity
were made. Since the sample size was predefined by
the parent study, no formal sample size calculations
were made.
The parent study consisted of a Pilot Stage
cohort (N = 6) and a Primary Stage cohort (N = 35)
and included patients randomized after reaching
post-surgical eligibility criteria. In the parent study
analyses, it was found that the Pilot Stage and Primary
Stage populations differed only slightly in baseline
characteristics and outcome at Week 40 [5]. Hence,
for this exploratory open-label extension study, it was
decided prospectively to shift the focus of the effi-
cacy analyses to the overall population to make best
possible use of the data from all 41 patients. Thus,
the data presented in tables and figures here are for
the entire population. Results for the Primary Stage
cohort alone, however, are presented in Supplemen-
tary Material, Appendix D.
The primary endpoint was compared between
treatment groups using a mixed-effect model with
repeated measures (MMRM) adjusted for the base-
line value. Secondary and supplementary efficacy
endpoints were analyzed using either the MMRM or
an analysis of covariance (ANCOVA) model adjusted
for the baseline value of the respective assessment.
Treatment response rates were analyzed by means of
Fisher’s exact test, and correlation testing was done
with non-parametric Spearman rank correlation anal-
yses. No corrections for multiple comparisons were
made, and no hierarchical approach to the secondary
endpoints was employed.
RESULTS
Patients
All 41 patients randomized and treated in the par-
ent study were enrolled and completed the extension
study. Demographic and baseline Parkinson’s disease
characteristics are summarized in Table 1.
Drug delivery
As in the parent study, compliance was very high:
401 (97.8%) of 410 scheduled intraputamenal GDNF
infusions were administered as an outpatient proce-
dure during the extension trial period. Altogether,
48 (12.0%) infusions were interrupted or terminated
early, predominantly as a safety shutdown due to
mechanical pressure increases in one or several infu-
sion lines.
Mean gadolinium-evidenced coverage on MRI at
study end (Week 80/e40) was consistently high across
the left and right hemispheres in both treatment
groups (ranging from 67.9 ± 21.9% to 74.3 ± 14.5%
for putamenal VOI coverage, and from 48.3 ± 21.2%
to 57.2 ± 21.5% for total putamen coverage). These
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Table 1
Demographic and Parkinson’s Disease Characteristics at Screening
Characteristic GDNF/GDNF Placebo/GDNF
(N = 21) (N = 20)
Age – years 55.9 ± 8.8 54.3 ± 7.6
Male sex - no. (%) 9 (42.9) 13 (65.0)
Race - no. (%)
White 21 (100) 19 (95.0)
Asian 0 1 (5.0)
OFF-state Hoehn and Yahr stage - no. (%)
Stage 2 11 (52.4) 5 (25.0)
Stage 2.5 4 (19.0) 9 (45.0)
Stage 3 6 (28.6) 6 (30.0)
Disease duration – years
Since first motor symptom 10.6 ± 5.0 10.6 ± 5.5
Since original diagnosis 8.6 ± 4.4 7.9 ± 3.5
UPDRS motor score
OFF-state 36.0 ± 7.7 36.3 ± 6.2
ON-state 15.7 ± 5.8 16.6 ± 4.6
Levodopa response - %a 56.9 ± 11.3 54.2 ± 10.0
OFF-time per day – hours 6.3 ± 2.0 6.0 ± 2.0
aPercentage improvement in UPDRS motor score following a levodopa challenge. As shown
in Table 1, the baseline groups appeared well matched. There were, however, two variables
with noticeable differences between the groups: gender and H&Y score. Regarding gender,
we had 9 (42.9%) GDNF males vs. 13 (65.0%) Placebo males in the study. We do not think
that this biased the results, however, as there is nothing in the literature to indicate gender
bias with GDNF treatment. With regard to H&Y score, we had 11 GDNF vs. 5 Placebo
H&Y score 2 patients and 4 GDNF vs. 9 Placebo H&Y score 2.5 patients. The relevance
of these chance differences is likely small and we think it reassuring that the aggregate of
H&Y score 2 and 2.5 patients was similar in both groups (15 GDNF vs. 14 Placebo), and
that H&Y score 3 was the same in both groups (6 vs. 6). Furthermore, we performed post
hoc covariate analyses for a number of covariates including both gender and H&Y score
at screening and the treatment effect was neither enhanced nor diminished when assessing
these single covariates.
values are similar to the coverage observed at the end
of the parent study (Week 40) [5].
Clinical outcomes
From baseline (Week 0) to the end of treatment
(Week 80/e40), the OFF state UPDRS motor score
improved by 26.7 ± 20.7% (mean ± standard devia-
tion) in the GDNF/GDNF group and by 27.6 ± 23.6%
in the placebo/GDNF group, with no significant dif-
ference between the groups (least squares [LS] mean
difference: 0.4%, 95% CI: –13.9, 14.6; p = 0.96;
Table 2); therefore, the primary outcome of the exten-
sion trial was not met.
Likewise, none of the secondary or supplementary
outcomes spanning the entire 80-week period, except
for change in L-DOPA equivalent dose, showed a
significant difference, in either percentage or abso-
lute change from baseline to Week 80/e40, between
the GDNF/GDNF group and the placebo/GDNF
group (Table 2). As an exception, the increase in
the daily L-DOPA equivalent dose from baseline
to Week 80/e40 was smaller in the GDNF/GDNF
group (59 ± 194 mg) than in the placebo/GDNF
group (289 ± 365 mg, LS mean difference: –233 mg,
95% CI: –419, –47; p = 0.02, Table 2). The mean
total daily L-DOPA dose increased by 36 ± 186 mg
from baseline in the GDNF/GDNF group as com-
pared to 160 ± 230 mg in the placebo/GDNF group
(p = 0.0769).
By Week 80/e40, the OFF state UPDRS
motor score improved by 9.6 ± 6.7 points in the
GDNF/GDNF group and by 9.0 ± 7.8 points in the
placebo/GDNF group (Table 2, Fig. 1A). Compared
to baseline, improved or stable OFF state UPDRS
motor scores were seen in 37/41 patients (90%) across
both treatment groups (Fig. 1C).
The OFF state UPDRS ADL score showed mean
absolute improvements from baseline of 6.9 ± 5.5
points in the GDNF/GDNF group and by 4.6 ± 4.7
points in the placebo/GDNF group by Week 80/e40
(Table 2, Fig. 1B). Absolute changes in OFF state
UPDRS motor and ADL scores in the GDNF/GDNF
group at Week 80/e40 were significantly larger than
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Table 2
Efficacy Outcomes
Outcome Category GDNF/GDNF Placebo/GDNF Least Squares Mean
Variable (N = 21) (N = 20) Difference vs. Placebo
Baseline Week 80 Change Baseline Week 80 Change (95% CI); p
UPDRS scores
Motor (III) OFF 36.0 ± 11.7 26.4 ± 11.3 –9.6 ± 6.7 32.2 ± 8.3 23.2 ± 9.0 –9.0 ± 7.8 –0.0 (–4.4, 4.4); 0.99*
–26.7 ± 20.7% 27.6 ± 23.6% 0.4% (–13.9, 14.6); 0.96*
Motor (III) ON 16.3 ± 5.6 15.0 ± 6.0 –1.4 ± 4.8 16.3 ± 7.2 14.8 ± 6.0 –1.6 ± 4.1 –0.2 (–2.9, 2.6); 0.91*
–7.0 ± 32.3% 5.1 ± 22.7% –3.7% (–21.7, 14.2); 0.67*
ADL (II) OFF 18.5 ± 6.4 11.7 ± 4.9 –6.9 ± 5.5 16.9 ± 5.8 12.3 ± 6.6 –4.6 ± 4.7 –1.7 (–4.6, 1.2); 0.25*
–34.3 ± 22.3% 28.2 ± 26.2% –4.4% (–20.2, 11.4); 0.58*
ADL (II) ON 5.5 ± 4.1 2.9 ± 3.0 –2.6 ± 4.2 5.7 ± 3.7 3.9 ± 3.2 –1.8 ± 3.5 –0.8 (–3.0, 1.3); 0.43*
–33.9 ± 62.6% 32.3 ± 52.0% –3.3% (–40.1, 33.5); 0.86*
Total (II+III) OFF 55.0 ± 16.7 37.9 ± 14.9 –17.1 ± 8.6 49.1 ± 11.0 35.5 ± 13.0 –13.6 ± 10.0 –2.6 (–8.3, 3.2); 0.37*
–31.3 ± 14.8% –28.3 ± 19.8% –3.3% (–14.6, 8.0); 0.56*
Total (II+III) ON 21.8 ± 8.4 17.4 ± 7.6 –4.4 ± 6.9 22.0 ± 8.5 18.6 ± 6.4 –3.3 ± 6.1 –1.6 (–5.3, 2.2); 0.40*
–17.5 ± 31.9% –11.3 ± 23.1% –7.9% (–25.7, 9.9); 0.37*
Timed tapping – no.
OFF-state 43.1 ± 15.0 63.8 ± 22.6 20.7 ± 15.4 42.4 ± 9.4 59.1 ± 17.9 16.7 ± 13.0 3.9 (–5.1, 12.9); 0.39*
ON-state 64.2 ± 17.6 79.9 ± 22.7 15.7 ± 13.6 61.0 ± 17.4 73.6 ± 19.2 12.7 ± 10.0 3.4 (–4.2, 11.0); 0.37*
Timed walking – sec
OFF-state 58.4 ± 97.3 27.6 ± 52.0 –27.0 ± 106.5 17.6 ± 10.8 11.7 ± 2.9 –4.3 ± 6.4 3.4 (–25.5, 32.3); 0.81*
ON-state 11.0 ± 2.6 10.4 ± 1.8 –0.6 ± 1.8 10.4 ± 1.9 9.8 ± 1.6 –0.7 ± 1.4 0.3 (–0.5, 1.0); 0.47*
Motor fluctuation
diary ratings – hrs
Total OFF-time 6.1 ± 1.7 4.5 ± 1.8 –1.5 ± 1.4 4.8 ± 2.2 4.0 ± 2.1 –0.8 ± 2.8 –0.2 (–1.4, 1.1); 0.80*
Good-quality
ON-time
10.2 ± 2.0 11.8 ± 2.2 1.6 ± 1.5 12.5 ± 2.6 13.1 ± 3.1 0.5 ± 3.0 0.6 (–1.0, 2.1); 0.46*
ON-time with
troublesome
dyskinesias
0.6 ± 1.2 0.4 ± 1.0 –0.2 ± 0.8 0.5 ± 1.0 0.4 ± 0.7 –0.1 ± 1.2 –0.1 (–0.6, 0.5); 0.80*
Total daily dose – mg
L-DOPA 639 ± 306 675 ± 310 36 ± 186 561 ± 284 721 ± 391 160 ± 230 –121 (–256, 14); 0.08†
L-DOPA equivalent 1,011 ± 340 1,071 ± 396 59 ± 194 954 ± 383 1,243 ± 552 289 ± 365 –233 (–419, –47); 0.02†
*MMRM with baseline variable as a covariate, treatment group and visit and treatment group*visit as fixed effects, and patient within
treatment group as a random effect. †ANCOVA model with baseline variable as a covariate and treatment group as a factor. Notes: (1)
One GDNF/GDNF patient had a conus injury due to a car accident and was included in the UPDRS motor scores without items 22, 27,
28, 29, and 30. The same patient was excluded from the UPDRS ADL and total scores. (2) Timed tapping numbers are averages of left
and right. (3) UPDRS parts I and IV, EQ-5D, body weight, Simplified Nutritional Appetite Questionnaire, Questionnaire for Impulsive-
Compulsive Disorders in Parkinson’s disease, Montreal Cognitive Assessment, Mattis Dementia Rating Scale, Stroop test, Frontal Systems
Behavioral Scale, Deary-Liewald reaction time, verbal fluency assessment, Beck Depression Inventory, and University of Pennsylvania
Smell Identification Test remained essentially unchanged between baseline and Week 80 in both groups and did not reveal any significant
treatment differences between GDNF/GDNF and placebo/GDNF.
the corresponding changes in the placebo group at
Week 40 (motor: –9.6 ± 6.7 vs. –3.8 ± 4.2 points,
p = 0.0108; ADL: –6.9 ± 5.5 vs. –1.0 ± 3.7 points,
p = 0.0003).
Improvements in total OFF time and good-quality
ON time per day were observed in both groups during
the extension study (Table 2, Fig. 2A-B). Compared
to baseline, mean total OFF time per day fell by
1.5 ± 1.4 hours in the GDNF/GDNF group and by
0.8 ± 2.8 hours in the placebo/GDNF group. Good-
quality ON time increased by 1.6 ± 1.5 hours in the
GDNF/GDNF group and by 0.5 ± 3.0 hours in the
placebo/GDNF group.
In a responder analysis at Week 80/e40, 11 (52%)
GDNF/GDNF patients and 9 (45%) placebo/GDNF
patients showed a ≥ 10 absolute points improvements
in OFF state UPDRS motor score from baseline.
The proportion of patients showing such a response
after only 40 weeks of treatment with GDNF by the
end of the extension study (placebo/GDNF group at
Week 80/e40) was therefore similar to that seen in the
GDNF-receiving patients at Week 40 in the parent
study (GDNF/GDNF group at Week 40:9/21 [43%]).
Twenty (95%) GDNF/GDNF patients and fourteen
(70%) placebo/GDNF patients reached or exceeded
thresholds for clinically meaningful improvements
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Fig. 1. A. OFF State UPDRS Motor Score: Change over Time. Note: Data points represent means, and error bars represent standard errors.
One GDNF/GDNF patient had a conus injury due to a car accident and was included in the motor score without items 22, 27, 28, 29, and
30. B. OFF State UPDRS ADL Score: Change over Time. Note: Data points represent means, and error bars represent standard errors. One
GDNF/GDNF patient had a conus injury due to a car accident and was excluded from the analysis. C. OFF State UPDRS Motor Score:
Frequency Distribution of Change at Week 80/e40. Note: One GDNF/GDNF patient had a conus injury due to a car accident and was included
in the motor score without items 22, 27, 28, 29, and 30.
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Fig. 2. A. Total OFF Time per Day: Change over Time. Note: Data points represent means, and error bars represent standard errors. B.
Total Good-Quality ON Time per Day: Change over Time. Note: Data points represent means, and error bars represent standard errors.
Total good-quality ON time per day is defined as the sum of ON time per day without dyskinesias + ON time per day with non-troublesome
dyskinesias.
by Week 80/e40 compared to baseline in OFF state
UPDRS motor score (≥10 points), and/or OFF state
UPDRS ADL score (≥5 points) and/or good-quality
ON time per day (≥1 hour) [6, 7]. The numbers of
patients who reached / exceeded thresholds in three or
two of the above outcomes (triple and double respon-
ders at Week 80) were: 15 (71.4%) of 21 patients
in the GDNF/GDNF group (4 triple responders, 11
double responders) vs. 8 (40%) of 20 patients in the
placebo/GDNF group (5 triple responders, 3 double
responders.
SAFETY
AEs were reported for all 41 patients between
Week 40 and Week 80/e40 (Table 3). No patient
had an AE leading to discontinuation of study
medication. As in the parent study, the most fre-
quently reported AEs (10 or more patients overall)
included dyskinesia, Lhermitte’s sign, paraesthesia,
fall, ON/OFF phenomenon, and freezing. No differ-
ential pattern was discernible between the treatment
groups, and overall frequencies were similar to the
GDNF group by the end of the parent study [5]. The
overall frequency of AEs of special interest was sim-
ilar in both treatment groups (GDNF/GDNF: 76%,
placebo/GDNF: 85%).
Serious AEs were reported for 8 (20%) patients
overall (GDNF/GDNF: 7, placebo/GDNF: 1), and
were all judged to be unrelated to study medication:
device-related events (3), traumatic muscle rupture
(1), menorrhagia requiring hysterectomy and post-
operative infection (1), multifactorial confusion and
fluctuating cognition (1), recurrence of pre-study
depression and paranoia (1), and osteoarthritis (1).
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Table 3
Adverse Events Experienced by at Least 5 Patients Overall
Adverse Event – no. (%) GDNF/GDNF Placebo/GDNF Total
(N = 21) (N = 20) (N = 41)
Patients with at least one AE 21 (100) 20 (100) 41 (100)
Dyskinesia 8 (38) 9 (45) 17 (42)
Lhermitte’s sign 9 (43) 4 (20) 13 (32)
Nasopharyngitis 7 (33) 6 (30) 13 (32)
Paresthesia 6 (29) 7 (35) 13 (32)
Fall 5 (24) 7 (35) 12 (29)
ON and OFF phenomenon 4 (19) 7 (35) 11 (27)
Freezing phenomenon 7 (33) 3 (15) 10 (24)
Application site infection 5 (24) 4 (20) 9 (22)
Dystonia 5 (24) 4 (20) 9 (22)
Headache 4 (19) 5 (25) 9 (22)
Back pain 3 (14) 5 (25) 8 (20)
Muscle spasms 2 (10) 6 (30) 8 (20)
Contusion 4 (19) 3 (15) 7 (17)
Pain in extremity 5 (24) 2 (10) 7 (17)
Urinary tract infection 3 (14) 4 (20) 7 (17)
Application site erythema 2 (10) 4 (20) 6 (15)
Dizziness 3 (14) 3 (15) 6 (15)
Joint injury 4 (19) 2 (10) 6 (15)
Nausea 4 (19) 2 (10) 6 (15)
Constipation 2 (10) 3 (15) 5 (12)
Drug effect decreased 2 (10) 3 (15) 5 (12)
Most frequent device-related AEs included appli-
cation site erythema and infection. No intracranial
infections occurred during the extension study trial.
Quantifiable GDNF plasma concentrations were
found in 10 (5%) blood samples from 3 patients
between Week 40 and Week 80/e40. However, no
GDNF-binding serum antibodies were identified in
the study at any time.
DISCUSSION
We did not observe significant differences in the
primary or secondary outcome measures spanning the
entire 80-week period between the group receiving
GDNF for 80 weeks and the group receiving placebo
for the first 40 weeks followed by GDNF for the sec-
ond 40 weeks (Table 2). It is probably not surprising,
however, that the primary and secondary endpoints
were not met given that there were no significant dif-
ferences between the primary or secondary clinical
outcomes in the double-blind parent investigation.
In such a situation, it was unlikely that differences
between groups would emerge while treating both
groups with open-label GDNF for 40 weeks.
The extension study was initiated approximately
two and a half years before the parent study was com-
pleted and read out. While patients knew that they
were on GDNF in the extension trial, they were kept
blinded to their treatment assignment in the parent
study. However, the extension study was neither con-
ceived nor powered as a delayed-start investigation of
the type previously employed to assess putative neu-
roprotective agents in Parkinson’s disease [8]. Indeed,
such a design may not be suitable for an agent that,
like GDNF, is hypothetically capable of both neu-
rone restoration and protection and thus, may lead to
clinical improvement rather than disease stabilization
alone.
An important question is whether the two stud-
ies, parent and extension, in aggregate, have fully
tested the growth factor hypothesis with respect to
the neurorestorative potential of GDNF. When dis-
cussing the results of the parent study [5], we raised
the possibility that clinical effects may, at least in
part, lag behind biological changes during disease
reversal or need a longer period of repeated expo-
sure to drug to develop. Such a supposition is based
on the premise that whilst functional changes due to
restoration of the dopamine phenotype of affected
neurons may occur early [9], there may be delays
between terminal sprouting, synapse formation and
circuit reestablishment, and subsequent improvement
in measurable clinical function [10].
The above would imply that there should be con-
tinued or added benefit during the second 40 weeks
of treatment with GDNF. The limitation to test-
ing this implication is that we no longer have the
310 A.L. Whone et al. / Extended Intermittent GDNF in Parkinson’s Disease
benefit of a control arm, due to the open label active
treatment nature of the extension study, and hence
any clinical benefit must be judged in that light. That
said, we can note that although there was no sta-
tistical difference in OFF state UPDRS motor and
ADL scores between the groups at Week 40 [5], the
corresponding Week 80 results in the GDNF/GDNF
group were significantly different from the Week
40 results in the placebo/GDNF group. This, how-
ever, could have been due to a second placebo effect
as patients moved into the Extension Study, from
which point they knew they were receiving GDNF
whatever they had received in the first 40 Weeks.
This pre-specified analysis was undertaken to com-
pare the effects of treatment with GDNF over 80
weeks against 40 Weeks of placebo and was per-
formed because up to 40 Weeks of placebo (the end
of the double-blind study) is the longest period of
treatment with placebo alone data we have. Whilst
we recognise this does not serve as a control it is
an additional comparison to consider whilst accept-
ing its limitations. The curves for OFF state UPDRS
motor score converge over the course of the extension
study (Fig. 1A), and whilst the curves for OFF state
UPDRS ADL score (Fig. 1B) and Parkinson’s disease
diary-based outcomes (Fig. 2A, B) do not converge,
they do not show significant differences between the
groups at Week 80 either. In consequence, the above
raised question of whether clinical effects lag behind
biological changes during disease reversal or need a
longer period of repeated exposure to drug to develop
cannot be answered definitively on the basis of the
extension study results. Conceivably, however, higher
GDNF doses and/or a longer duration of repeated
tissue exposure would have been required to show
benefit in the parent investigation [5].
The mean improvements from baseline to Week
80 in OFF state UPDRS motor and ADL scores
and Parkinson’s disease diary ratings were equivalent
to moderate-to-large clinical effects [6, 7], although
we recognise that such magnitude of change could
represent a placebo response in an open label investi-
gation where patients knew they were receiving active
treatment. Given the requirement for a neurosurgical
approach, some would suggest it might be appropri-
ate to consider the magnitude of the symptomatic
improvement achieved with deep brain stimulation
(DBS) as a reference. In a recent open-label DBS
study that included a not dissimilar patient cohort, the
VANTAGE investigation, improvements from base-
line in OFF state motor UPDRS and ADL scores
and patient diaries were seen at 52 weeks that were
approximately twofold larger than with GDNF at 80
weeks [11]. DBS, however, is a matured therapy and
the symptomatic improvement achieved with DBS is
not hypothesised to be via a neurorestorative mech-
anism and hence comparison with an experimental
disease-modifying approach is potentially not valid.
Placebo effects are well recognized in Parkinson’s
disease [12]. The size of these effects may reflect
the magnitude of the intervention and the antici-
pated benefits, and could therefore be large in a study
involving initial neurosurgery followed by intraputa-
menal infusions via a skull-mounted port every 4
weeks over a total of 80 weeks [13–15]. In addi-
tion, a second placebo response may have occurred
as the patients switched from double-blind treatment
to known open-label GDNF therapy in the exten-
sion study [16]. In this context, it is worth noting
that the new occurrence of certain AEs, in particular
Lhermitte’s phenomenon or paraesthesias, may have
signalled to patients that their treatment changed in
the extension trial. Likewise, investigator bias, once it
was known that patients were receiving GDNF, may
have played a part in the development of the clini-
cal benefits over baseline observed after 18 months.
It is also possible that the overall placebo response
was enhanced by putamenal tissue disruption as a
result of catheter implantation and repeated high-
pressure CED infusions, since mechanical injury has
been shown to induce dopaminergic axonal sprouting
and increase dopaminergic activity in the nigrostriatal
system, primarily via a GDNF- and BDNF-dependent
mechanism mediated by activated macrophages and
microglia [17–19]. In future studies, it may be use-
ful to consider the addition of a standard-of-care arm
and/or the replacement of the placebo arm (which
may in fact be an experimental treatment arm) with a
sham surgery arm to derive a better understanding of
these mechanisms and the true effect size attributable
to GDNF.
In the discussion of the parent study paper [5], we
also contemplated that the inability to prove clinical
benefit at 40 weeks may, at least in part, be related
to the GDNF dose used in the trial. This question
remains unanswered at the end of the extension study.
Dosing is a complex issue in the context of intermit-
tent CED, and while we did integrate the available
preclinical and clinical information when defining
the dose and delivery scheme, it is worth noting
that although double the prior tested GDNF con-
centration was employed, (0.2g/L in this and the
allied parent investigation versus 0.1g/L in previ-
ous clinical trials [2–4]), the total dose given every 4
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weeks (240g; 120g/putamen) was less than one
third of the monthly cumulative dose administered in
previous studies which employed continuous dosing
of GDNF via abdominal pumps [2–4]. This is poten-
tially important considering that the neurorestorative
effects of GDNF on its target neurons are known to be
dose-dependent and tissue-exposure dependent [20,
21]. Using a higher dose with intermittent administra-
tion, however, would have required a higher infusate
GDNF concentration (e.g., 0.6g/L) which could
not be implemented before addressing concerns about
unexpected cerebellar toxicity in rhesus monkeys that
had been treated with a similar concentration, albeit
in a continuous dosing study and at a total dose well
beyond the clinical range [22]. In the meantime, the
safety of the higher concentration, when used inter-
mittently, has been confirmed [23], thus enabling its
clinical use in the future.
We are aware of the history of AAV2-neurturin,
which underwent clinical retesting based on “sup-
portive” and post-hoc evidence from a Phase II study
that did not reach its primary endpoint [24]. This fur-
ther AAV2-neurturin trial, however, which included
a higher dose and longer treatment duration, again
generated negative data [25]. That said, there are
several important differences between the GDNF
and the AAV2-neurturin programmes, including the
improvement in [18F]DOPA uptake with GDNF, that
was not seen with AAV2-neurturin, and the spa-
tial distribution achieved by the intermittent CED
paradigm employed with GDNF.
The breadth of response to an infused trophic
factor in a broad-spectrum disorder such as Parkin-
son’s disease is a priori likely to be wide and
the factors determining the limits of any potential
gain in an individual patient are yet to be estab-
lished. While the covariate analyses in the parent
study did not reveal any characteristics that pre-
dicted benefit, it is potentially noteworthy that 95%
of patients receiving GDNF for 80 weeks passed
the thresholds for meaningful clinical improvements
in one or more of the core outcome measures [6,
7]. In a disorder which to date has no approved
therapy for disease modification, this potential hint
at broad-spectrum applicability is not unimportant.
It is conceivable that certain neurorestorative or
neuroprotective approaches may be more applica-
ble to selected subgroups of Parkinson’s patients
depending on the nature of the underlying molecular
dysfunction. Therapies targeting protein aggrega-
tion, mitophagy or inflammation may require patient
stratification where the target is a top-down driver
of disease progression. Trophic factors, including
GDNF, however, may not necessarily require person-
alized stratification to be beneficial given the potential
for improvement via a final common pathway.
Intermittent intraputamenal administration of
GDNF at the selected dose (240g every 4 weeks)
over 80 weeks was well tolerated and safe and, con-
trary to the historic continuous dosing Phase II study
[4], did not induce anti-GDNF antibody formation.
Treatment compliance was high (97.8%) and there
were neither drop-outs during the study nor any unto-
ward problems with OFF state dyskinesias of the type
reported in a previous foetal graft study [26].
In conclusion, neither the parent nor the exten-
sion study reached their primary endpoints. The
integrated results of the two studies suggest that:
Attending on an out-patient basis over 18 months,
to receive intraputamenal infusions every 4 weeks
via a skull-mounted port, is feasible; As evidenced
by increased [18F]DOPA PET findings in the parent
study, our novel method of administration enables
a putamen-wide target tissue engagement; Intermit-
tent intraputamenal administration of GDNF (240g
every 4 weeks) for 80 weeks is well tolerated;
and, Further testing of the growth factor hypoth-
esis in a larger-scale study will likely require 80
weeks of randomized treatment and / or a higher
dose to definitively determine whether GDNF has
a future role as a neurorestorative treatment for
Parkinson’s disease.
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